FOSAMAX PLUS D Drug Patent Profile

When do Fosamax Plus D patents expire, and when can generic versions of Fosamax Plus D launch?

Fosamax Plus D is a drug marketed by Organon Llc and is included in one NDA.

The generic ingredient in FOSAMAX PLUS D is alendronate sodium; cholecalciferol. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alendronate sodium; cholecalciferol profile page.

Summary for FOSAMAX PLUS D

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for FOSAMAX PLUS D

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FOSAMAX PLUS D	Tablets	alendronate sodium; cholecalciferol	70 mg/2800 IU and 70 mg/5600 IU	021762	1	2007-11-20

US Patents and Regulatory Information for FOSAMAX PLUS D

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Llc	FOSAMAX PLUS D	alendronate sodium; cholecalciferol	TABLET;ORAL	021762-001	Apr 7, 2005		RX	Yes	No
Organon Llc	FOSAMAX PLUS D	alendronate sodium; cholecalciferol	TABLET;ORAL	021762-002	Apr 26, 2007		RX	Yes	Yes

International Patents for FOSAMAX PLUS D

See the table below for patents covering FOSAMAX PLUS D around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	9717850
Finland	952685
China	1166365
Slovenia	1175904
Luxembourg	88714
Singapore	139556	METHOD FOR INHIBITING BONE RESORPTION
Spain	2150979

Supplementary Protection Certificates for FOSAMAX PLUS D

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0998292	PA2006002,C0998292	Lithuania		PRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824
1175904	C01175904/01	Switzerland		FORMER OWNER: SCHERING CORPORATION, US
0998292	91222	Luxembourg		91222, EXPIRES: 20200824
1175904	PA2007007	Lithuania		PRODUCT NAME: ACIDUM ALENDRONICUM NATRIUM, COLECALCIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001 2005 08 24 EU/1/05/310/002 2005 08 24 EU/1/05/310/003 2005 08 24 EU/1/05/310/004 2005 08 24 EU/1/05/310/00 20050824
0998292	CA 2006 00005	Denmark		PRODUCT NAME: ALENDRONSYRE, NATRIUMTRIHYDRAT, COLECALCIFEROL
1175904	91364	Luxembourg		91364, EXPIRES: 20200826
1175904	2007C/048	Belgium		PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826

FOSAMAX PLUS D: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

FOSAMAX PLUS D (alendronate sodium + vitamin D3) is a combination medication primarily indicated for the prevention and treatment of osteoporosis in postmenopausal women and other at-risk populations. Given its established market presence, patent status, and competitive landscape, the drug presents a significant but evolving investment opportunity. This report analyzes current market dynamics, forecasted financial performance, key competitors, regulatory considerations, and strategic pathways to maximize return on investment.

Market Overview of FOSAMAX PLUS D

Parameter	Details
Active Ingredients	Alendronate sodium + Vitamin D3 (Cholecalciferol)
Indications	Postmenopausal osteoporosis, Paget's disease, glucocorticoid-induced osteoporosis
Market Launch	2004 (varies by region)
Global Market Size (2022)	Estimated at $2.5 billion (Source: IQVIA)
Projected CAGR (2023–2028)	3.5% (Source: MarketsandMarkets)

Key Markets

Region	Market Size (2022)	Growth Rate	Notes
North America	$1.2 billion	4%	Leading market, high penetration
Europe	$700 million	3.2%	Mature, but with growth opportunities
Asia-Pacific	$400 million	6.5%	Rapid expansion, increasing osteoporosis awareness
Latin America	$150 million	2.8%	Emerging opportunities

Market Drivers

• Aging populations globally
• Growing osteoporosis prevalence among women over 50
• Increased diagnosis rates
• Product differentiation via combination formulations
• Favorable reimbursement policies in developed countries

Market Constraints

• Patent expirations leading to generics
• Safety concerns related to long-term bisphosphonate use (e.g., atypical femoral fractures)
• Competition from alternative therapies (denosumab, teriparatide, SGLT2 inhibitors for related indications)
• Regulatory risks (e.g., safety warnings, label modifications)

---

Investment Scenario Analysis

Current Brand Position and Patent Status

Aspect	Details
Patent Expiry	Approximately 2015–2020 (varies by jurisdiction)
Impact	Patent expirations have ushered in generic competition lowering prices by 60–80% (Source: FDA Orange Book)
Brand Strength	Established prescriber base, trusted efficacy, and safety record

Generic Competition and Market Share

Period	Market Share (Brand)	Market Share (Generics)
Pre-2015	~85%	~15% (brand dominant)
2022	~30%	~70% (generics dominate)

Revenue Trends (2015–2022)

Year	Estimated Revenue (USD millions)	Comments
2015	$850	Peak pre-generic entry
2018	$600	Sharp decline after generics entry
2022	$400	Stabilization at lower level

Forecasted Financial Trajectory (2023–2030)

Year	Projected Revenue (USD millions)	Assumptions
2023	$320	Moderate market share recovery via new formulations or indications
2025	$350	Ensuing stabilization with differentiated dosing or combo therapies
2030	$400	Potential plateau due to market saturation and generic competition

Note:Revenue projections assume moderate competition, ongoing patent litigation, and evolving regulatory environment.

---

Market Dynamics

Competitive Landscape

Competitor	Product	Market Position	Strengths	Weaknesses
Denosumab (Prolia)	Monoclonal antibody	Alternative to bisphosphonates	Higher efficacy, less GI irritation	Higher cost, injection-based
Teriparatide (Forteo)	Recombinant PTH	Anabolic treatment option	Effective in severe cases	Expensive, limited duration of use
Generic Alendronate + D3	Multiple manufacturers	Price leader post-patent	Cost-effective	Perceived lower safety profile

Regulatory and Safety Considerations

• Label updates reflecting risk of atypical femur fractures and osteonecrosis of the jaw.
• EMA and FDA guidelines emphasizing risk-benefit analysis.
• Ongoing real-world evidence monitors post-marketing safety.

Pricing Dynamics

Segment	Pricing Range	Notes
Brand (FOSAMAX PLUS D)	$150–$200 per month	Higher in U.S., variable elsewhere
Generics	$30–$50 per month	Significant price erosion

Reimbursement Policies

• Favorable in North America and Europe for osteoporosis management.
• Adoption driven by formulary preferences.
• Price competition influences prescribing behavior.

---

Financial Trajectory and Investment Implications

Factor	Impact	Strategic Opportunity
Patent Expiry	Revenue decline	Focus on lifecycle management, new indications
Generics Entry	Price erosion	Diversify portfolio, invest in combination innovations
New Formulations	Potential premium pricing	Develop once-weekly or injectable versions
Market Expansion	Growth in Asian-Pacific	Local partnerships, market-specific formulations

Potential Growth Pathways

• Line Extensions: Introducing next-generation formulations targeting compliance.
• New Indications: Osteoporosis in men, anti-fracture studies.
• Digital & EHR Integration: Enhance prescribing tracking and adherence.
• Partnerships: Collaborations with generic manufacturers for co-marketing.

---

Comparison with Alternative Osteoporosis Therapies

Therapy	Route	Efficacy	Safety Profile	Cost	Market Position
FOSAMAX PLUS D	Oral	Moderate	Good, safety concerns in long-term use	Competitive	Established, differentiated by combination
Denosumab	Subcutaneous	High	Osteonecrosis risk	Premium	Growing alternative, especially in high-risk patients
Teriparatide	Injection	High	Costly, limited duration	High	Severe cases, niche market
Generic Bisphosphonates	Oral	Similar	Similar	Low	Mainstay therapy in first-line treatment

---

Key Policies and Regulatory Outlook

Policy Aspect	Status	Implication
Patent Extensions	Varied by jurisdiction	Potential to delay generics in specific markets
Safe Use Guidelines	Updated periodically	Affects market perception and prescribing practices
Approval of New Formulations	Pending or approved	Can renew market interest

---

Summary of Investment Outlook

• Short Term: Revenue decline due to patent expiration and generic entry; focus on cost management.
• Mid Term: Stabilization through formulation innovations, lifecycle extension, and expanding indications.
• Long Term: Potential growth via off-label uses, sustained demand in aging populations, and digital health integration.

Key Takeaways

• FOSAMAX PLUS D remains a cornerstone osteoporosis treatment but faces competitive pressure from generics and alternative therapies.
• Investment strategies should prioritize lifecycle management, including new formulations and indications.
• Market expansion in Asia-Pacific offers a growth avenue, contingent on local regulatory approvals.
• Biosimilar and generic markets will dominate in volume, but premium pricing can be maintained through differentiated formulations.
• Regulatory landscapes will continuously influence market dynamics; proactive compliance and safety communication are essential.

FAQs

1. What is the current patent status of FOSAMAX PLUS D?

Patent protections for FOSAMAX PLUS D generally expired between 2015 and 2020 in major markets, leading to widespread generic competition ([1]). While proprietary formulations or delivery mechanisms may still be under patent in specific regions, the core active ingredients are no longer protected, impacting pricing and market share.

2. How does market competition influence the financial trajectory of FOSAMAX PLUS D?

Intensified generic competition has driven down prices by up to 80%, reducing revenue margins. As a result, the original brand’s revenue declined from approximately $850 million pre-patent expiry to around $400 million in 2022. To sustain profitability, focus has shifted to lifecycle extensions and novel formulations.

3. What are the primary growth opportunities for FOSAMAX PLUS D?

• Developing once-weekly formulations to improve adherence ([2])
• Expanding indications to osteoporosis in men and glucocorticoid-induced osteoporosis
• Entering emerging markets with high osteoporosis prevalence
• Collaborating with biosimilar producers to optimize market share

4. How are safety concerns affecting the market?

Long-term bisphosphonate use has been linked with atypical femoral fractures and osteonecrosis of the jaw ([3]). Regulatory agencies recommend caution and periodic reassessment, which can influence prescribing trends and reimbursement policies, potentially reducing sales if safety warnings impact consumer confidence.

5. What are the implications of regulatory policies for future revenue?

Stringent safety regulations and potential label restrictions may limit markets or require additional safety monitoring, possibly inflating costs and constraining growth ([4]). Conversely, favorable reimbursement environments and approvals for new formulations can enhance financial prospects.

---

References

1. FDA Orange Book. Patents and Exclusivity Data for FOSAMAX. [2022].
2. GlobalData. Osteoporosis Treatment Market Report. 2022.
3. FDA Safety Communications. Bisphosphonates and Risk of Atypical Femoral Fractures. 2019.
4. EMA Guidelines on Osteoporosis Management. 2021.

---

This analysis provides a strategic overview for stakeholders considering investment, licensing, or portfolio management related to FOSAMAX PLUS D, emphasizing current market conditions, future opportunities, and key risks.